These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35128732)

  • 1. Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme.
    O' Donovan B; Rodgers RM; Cox AR; Krska J
    Br J Clin Pharmacol; 2022 Jul; 88(7):3434-3446. PubMed ID: 35128732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals.
    McLernon DJ; Bond CM; Hannaford PC; Watson MC; Lee AJ; Hazell L; Avery A;
    Drug Saf; 2010 Sep; 33(9):775-88. PubMed ID: 20701410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
    Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
    Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK.
    Thompson A; Randall C; Howard J; Barker C; Bowden D; Mooney P; Munyika A; Smith S; Pirmohamed M
    J Clin Pharm Ther; 2019 Feb; 44(1):78-83. PubMed ID: 30206951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme.
    Krska J; Anderson C; Murphy E; Avery AJ
    Drug Saf; 2011 May; 34(5):429-36. PubMed ID: 21513365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing and further developing age-appropriate information for young people about reporting suspected adverse drug reactions.
    Bioletti L; ; Woodward C; Jadeja M; Hawcutt DB
    Br J Clin Pharmacol; 2024 Mar; 90(3):863-870. PubMed ID: 37990602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpreting adverse drug reaction (ADR) reports as hospital patient safety incidents.
    Davies EC; Green CF; Mottram DR; Pirmohamed M
    Br J Clin Pharmacol; 2010 Jul; 70(1):102-8. PubMed ID: 20642552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
    Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
    Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of patient reporting to the pharmacovigilance system: a systematic review.
    Inácio P; Cavaco A; Airaksinen M
    Br J Clin Pharmacol; 2017 Feb; 83(2):227-246. PubMed ID: 27558545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association.
    Vilhelmsson A; Svensson T; Meeuwisse A; Carlsten A
    BMC Pharmacol Toxicol; 2012 Dec; 13():19. PubMed ID: 23259410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients' contribution to drug safety in Catalonia: the interest of personal feelings on adverse drug reactions.
    Riera-Arnau J; Alvarado Aguirre LA; Garcia Doladé N; Vidal Guitart X; Figueras A; Cereza García G
    Eur J Clin Pharmacol; 2021 Apr; 77(4):637-642. PubMed ID: 33170306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Under-reporting of gastrointestinal bleeding associated with anticoagulant use using the UK Yellow Card Scheme.
    Shuttleworth P; Baker J; Clark E
    Int J Clin Pharm; 2023 Aug; 45(4):1014-1018. PubMed ID: 37269441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance Reports Received from Children and Young People, and Development of Information to Aid Future Reporting from this Age Group.
    Bhoombla N; Preston J; Ainsworth J; Bird H; Jadeja M; King C; Hawcutt DB
    Paediatr Drugs; 2020 Jun; 22(3):335-341. PubMed ID: 32253722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis.
    Hawcutt DB; Russell NJ; Maqsood H; Kouranloo K; Gomberg S; Waitt C; Sharp A; Riordan A; Turner MA
    Br J Clin Pharmacol; 2016 Dec; 82(6):1601-1612. PubMed ID: 27597136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review.
    Inch J; Watson MC; Anakwe-Umeh S
    Drug Saf; 2012 Oct; 35(10):807-18. PubMed ID: 22928729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports.
    Schifano N; Chiappini S; Castiglione F; Salonia A; Schifano F
    Low Urin Tract Symptoms; 2021 Apr; 13(2):230-237. PubMed ID: 33037767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
    Castillon G; Salvo F; Moride Y
    Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undergraduate and postgraduate pharmacovigilance education: A proposal for appropriate curriculum content.
    Herrera Comoglio R
    Br J Clin Pharmacol; 2020 Apr; 86(4):779-790. PubMed ID: 31770452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes.
    Cox AR; Marriott JF; Wilson KA; Ferner RE
    J Clin Pharm Ther; 2004 Feb; 29(1):31-5. PubMed ID: 14748895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.